Literature DB >> 19608301

[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation].

José M A Lobos Bejarano1, Miguel Angel Royo-Bordonada, Carlos Brotons, Luís Alvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Angel Lizcano, Antonio Gil-Núñez, Fernando de Alvaro, Pedro Conthe, Emilio Luengo, Alfonso Del Río, Olga Cortés, Ana de Santiago, Miguel A Vargas, Mercedes Martínez, Vicenta Lizarbe.   

Abstract

The present CEIPC Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD by means of dealing with its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care doctors in promoting a healthy life style, based on increasing physical activity, changing dietary habits, and not smoking. The therapeutic goal is to achieve a Blood Pressure<140/90mmHg, but in patients with diabetes, chronic kidney disease, or definite CVD, the objective is<130/80mmHg. Serum cholesterol should be<200mg/dl and cLDL<130mg/dl, although in patients with CVD or diabetes, the objective is<100mg/dl (80mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, with the objective guided by body mass index and waist circumference. In diabetic type 2 patients, the objective is glycated haemoglobin<7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to put the recommendations into practice.

Entities:  

Mesh:

Year:  2009        PMID: 19608301      PMCID: PMC7268884          DOI: 10.1016/j.aprim.2008.10.024

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  78 in total

Review 1.  New-onset diabetes and antihypertensive drugs.

Authors:  Giuseppe Mancia; Guido Grassi; Alberto Zanchetti
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

2.  The molecular basis of familial hypercholesterolemia in The Netherlands.

Authors:  S W Fouchier; J C Defesche; M W Umans-Eckenhausen; J P Kastelein
Journal:  Hum Genet       Date:  2001-11-09       Impact factor: 4.132

3.  A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom.

Authors:  K E Heath; S E Humphries; H Middleton-Price; M Boxer
Journal:  Eur J Hum Genet       Date:  2001-04       Impact factor: 4.246

4.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

5.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.

Authors:  Justin Ezekowitz; Finlay A McAlister; Karin H Humphries; Colleen M Norris; Marcello Tonelli; William A Ghali; Merril L Knudtson
Journal:  J Am Coll Cardiol       Date:  2004-10-19       Impact factor: 24.094

6.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Ilke Sipahi; Peter Libby; Joel S Raichlen; Christie M Ballantyne; Jean Davignon; Raimund Erbel; Jean Charles Fruchart; Jean-Claude Tardif; Paul Schoenhagen; Tim Crowe; Valerie Cain; Kathy Wolski; Marlene Goormastic; E Murat Tuzcu
Journal:  JAMA       Date:  2006-03-13       Impact factor: 56.272

7.  Predictors of new-onset kidney disease in a community-based population.

Authors:  Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

8.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

9.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

Authors: 
Journal:  Circulation       Date:  1998-06-09       Impact factor: 29.690

10.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

Authors:  Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  4 in total

1.  [Cardiovascular risk factors and Primary Care: evaluation and intervention].

Authors:  José María Lobos Bejarano; Carlos Brotons Cuixart
Journal:  Aten Primaria       Date:  2011-11-17       Impact factor: 1.137

2.  [Current clinical practice guidelines in type 2 diabetes: how should they be applied in primary care?].

Authors:  Jorge Navarro Pérez; Alejandro Navarro Adam; Domingo Orozco Beltrán; Vicente Gil Guillén; Concepción Carratalá Munuera
Journal:  Aten Primaria       Date:  2010-09       Impact factor: 1.137

3.  Social network, presence of cardiovascular events and mortality in hypertensive patients.

Authors:  C Menéndez-Villalva; M T Gamarra-Mondelo; A Alonso-Fachado; A Naveira-Castelo; A Montes-Martínez
Journal:  J Hum Hypertens       Date:  2014-12-11       Impact factor: 3.012

4.  [Basic guidelines for detecting sedentarism and recommendations for physical activity in primary care].

Authors:  Juan José Crespo-Salgado; José Luis Delgado-Martín; Orlando Blanco-Iglesias; Susana Aldecoa-Landesa
Journal:  Aten Primaria       Date:  2014-11-01       Impact factor: 1.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.